Symbols / IPHA $1.43 -5.30% Innate Pharma S.A.

Healthcare • Biotechnology • France • NMS
IPHA Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Fundamentals
Scroll to Statements
Market Cap 134.18M Enterprise Value 122.38M Income -49.18M Sales 9.01M Book/sh -0.27 Cash/sh 0.37
Dividend Yield — Payout 0.00% Employees 163 IPO — P/E — Forward P/E -2.27
PEG — P/S 14.90 P/B -5.23 P/C — EV/EBITDA -2.30 EV/Sales 13.59
Quick Ratio 1.14 Current Ratio 1.27 Debt/Eq — LT Debt/Eq — EPS (ttm) -0.65 EPS next Y -0.63
EPS Growth — Revenue Growth -46.70% Earnings 2026-05-13 ROA -38.85% ROE — ROIC —
Gross Margin 0.00% Oper. Margin -6.90% Profit Margin 0.00% Shs Outstand 93.83M Shs Float 65.90M Short Float 0.08%
Short Ratio 3.29 Short Interest — 52W High 2.63 52W Low 1.17 Beta 0.74 Avg Volume 22.95K
Volume 25.44K Target Price $6.00 Recom Strong_buy Prev Close $1.51 Price $1.43 Change -5.30%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.00
Mean price target
2. Current target
$1.43
Latest analyst target
3. DCF / Fair value
$-6.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.43
Low
$3.00
High
$8.00
Mean
$6.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-07 reit HC Wainwright & Co. Buy → Buy $5
2025-10-29 up HC Wainwright & Co. Neutral → Buy $5
2025-10-29 reit BTIG Buy → Buy $8
2025-09-18 down Leerink Partners Outperform → Market Perform $2
2025-09-18 down HC Wainwright & Co. Buy → Neutral —
2025-04-24 reit HC Wainwright & Co. Buy → Buy $11
2025-03-28 reit HC Wainwright & Co. Buy → Buy $12
2025-02-06 reit HC Wainwright & Co. Buy → Buy $12
2025-01-17 reit HC Wainwright & Co. Buy → Buy $12
2024-12-09 reit HC Wainwright & Co. Buy → Buy $12
2024-11-15 reit HC Wainwright & Co. Buy → Buy $12
2024-11-12 reit HC Wainwright & Co. Buy → Buy $12
2024-09-13 reit HC Wainwright & Co. Buy → Buy $12
2024-06-12 reit HC Wainwright & Co. Buy → Buy $12
2024-05-15 reit HC Wainwright & Co. Buy → Buy $12
2024-04-11 reit HC Wainwright & Co. Buy → Buy $12
2024-03-22 reit HC Wainwright & Co. Buy → Buy $12
2023-11-15 reit HC Wainwright & Co. Buy → Buy $12
2023-09-18 reit HC Wainwright & Co. Buy → Buy $12
2023-06-16 reit HC Wainwright & Co. Buy → Buy $12
News
RSS: Latest IPHA news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.79
-77.92%
12.62
-75.68%
51.90
+4.68%
49.58
Operating Revenue
2.29
-81.81%
12.56
-75.79%
51.89
+3.37%
50.20
Operating Expense
56.21
-12.44%
64.20
-0.58%
64.57
-2.17%
66.00
Research And Development
43.62
-16.08%
51.98
-7.22%
56.02
+8.44%
51.66
Selling General And Administration
11.00
-7.83%
11.93
+1.57%
11.75
-18.83%
14.47
General And Administrative Expense
11.00
-7.83%
11.93
+1.57%
11.75
-18.83%
14.47
Salaries And Wages
7.96
-7.01%
8.56
-3.23%
8.84
-13.56%
10.23
Other Gand A
3.04
-9.89%
3.38
+16.21%
2.91
-31.53%
4.24
Other Operating Expenses
1.59
+460.92%
0.28
+108.88%
-3.20
-2342.75%
-0.13
Total Expenses
56.21
-12.44%
64.20
-0.58%
64.57
-2.17%
66.00
Operating Income
-53.42
-3.59%
-51.58
-307.10%
-12.67
+22.87%
-16.43
Total Operating Income As Reported
-54.01
-4.72%
-51.58
-307.10%
-12.67
+77.94%
-57.42
EBITDA
-43.65
+6.96%
-46.91
-745.85%
-5.55
+54.83%
-12.28
Normalized EBITDA
-47.02
+0.27%
-47.14
-481.44%
-8.11
-127.46%
29.53
Reconciled Depreciation
5.09
+155.32%
1.99
+44.08%
1.38
-96.95%
45.41
EBIT
-48.74
+0.34%
-48.91
-605.70%
-6.93
+87.99%
-57.68
Total Unusual Items
3.37
+1352.16%
0.23
-90.94%
2.56
+106.13%
-41.80
Total Unusual Items Excluding Goodwill
3.37
+1352.16%
0.23
-90.94%
2.56
+106.13%
-41.80
Special Income Charges
-0.58
0.00
0.00
+100.00%
-41.00
Impairment Of Capital Assets
0.00
0.00
0.00
-100.00%
41.00
Restructuring And Mergern Acquisition
0.58
—
—
—
Net Income
-49.18
+0.59%
-49.47
-553.51%
-7.57
+86.97%
-58.10
Pretax Income
-49.18
+0.59%
-49.47
-553.51%
-7.57
+86.94%
-57.97
Net Non Operating Interest Income Expense
0.88
-53.07%
1.87
-26.25%
2.54
+883.33%
0.26
Interest Expense Non Operating
0.44
-22.26%
0.57
-11.56%
0.64
+122.22%
0.29
Net Interest Income
0.88
-53.07%
1.87
-26.25%
2.54
+883.33%
0.26
Interest Expense
0.44
-22.26%
0.57
-11.56%
0.64
+122.22%
0.29
Interest Income Non Operating
1.32
-45.92%
2.44
-23.29%
3.18
+481.87%
0.55
Interest Income
1.32
-45.92%
2.44
-23.29%
3.18
+481.87%
0.55
Other Income Expense
3.37
+1352.16%
0.23
-90.94%
2.56
+106.13%
-41.80
Gain On Sale Of Security
3.95
+1603.45%
0.23
-90.94%
2.56
+418.26%
-0.81
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-49.18
+0.59%
-49.47
-553.51%
-7.57
+86.97%
-58.10
Net Income From Continuing Operation Net Minority Interest
-49.18
+0.59%
-49.47
-553.51%
-7.57
+86.94%
-57.97
Net Income From Continuing And Discontinued Operation
-49.18
+0.59%
-49.47
-553.51%
-7.57
+86.97%
-58.10
Net Income Continuous Operations
-49.18
+0.59%
-49.47
-553.51%
-7.57
+86.94%
-57.97
Net Income Discontinuous Operations
0.00
0.00
0.00
+100.00%
-0.13
Normalized Income
-52.55
-5.72%
-49.70
-390.55%
-10.13
+37.33%
-16.17
Net Income Common Stockholders
-49.18
+0.59%
-49.47
-553.51%
-7.57
+86.97%
-58.10
Diluted EPS
-0.55
+9.84%
-0.61
-577.78%
-0.09
+87.67%
-0.73
Basic EPS
-0.55
+9.84%
-0.61
-577.78%
-0.09
+87.67%
-0.73
Basic Average Shares
89.59
+10.54%
81.05
-3.64%
84.11
+5.61%
79.64
Diluted Average Shares
89.59
+10.54%
81.05
-3.64%
84.11
+5.61%
79.64
Diluted NI Availto Com Stockholders
-49.18
+0.59%
-49.47
-553.51%
-7.57
+86.97%
-58.10
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2021-12-31
Total Assets
62.72
-43.53%
111.06
-36.61%
175.19
—
Current Assets
46.71
-45.52%
85.74
-42.07%
148.01
—
Cash Cash Equivalents And Short Term Investments
34.31
-57.52%
80.77
-12.64%
92.46
—
Cash And Cash Equivalents
28.09
-57.69%
66.40
-5.96%
70.61
—
Other Short Term Investments
6.22
-56.74%
14.37
-34.22%
21.85
—
Receivables
7.61
+363.18%
1.64
-96.47%
46.49
—
Accounts Receivable
0.39
-39.85%
0.65
-95.73%
15.23
—
Other Receivables
0.12
+31.46%
0.09
-14.42%
0.10
—
Taxes Receivable
7.10
+685.62%
0.90
-97.10%
31.15
—
Prepaid Assets
4.79
+43.86%
3.33
-63.28%
9.07
—
Other Current Assets
0.00
—
0.00
+0.00%
0.00
Total Non Current Assets
16.01
-36.77%
25.32
-6.84%
27.18
—
Net PPE
4.36
-15.14%
5.13
-18.81%
6.32
—
Gross PPE
4.36
-15.14%
5.13
-18.81%
6.32
—
Properties
0.00
0.00
0.00
—
Land And Improvements
1.97
-13.74%
2.29
-22.75%
2.96
—
Construction In Progress
0.00
0.00
0.00
—
Other Properties
2.38
-16.26%
2.85
-15.34%
3.36
—
Leases
—
1.27
-24.24%
1.68
—
Goodwill And Other Intangible Assets
0.00
0.00
-100.00%
0.42
—
Other Intangible Assets
—
—
0.42
-99.06%
44.19
Investments And Advances
10.46
+1.69%
10.28
+4.95%
9.80
—
Non Current Accounts Receivable
0.25
-97.31%
9.33
-11.62%
10.55
—
Non Current Deferred Assets
—
—
9.01
+79.12%
5.03
Non Current Deferred Taxes Assets
—
—
9.01
+79.12%
5.03
Other Non Current Assets
0.95
+64.70%
0.57
+560.92%
0.09
—
Total Liabilities Net Minority Interest
84.42
-17.41%
102.22
-17.08%
123.29
—
Current Liabilities
36.65
+11.12%
32.98
-16.79%
39.64
—
Payables And Accrued Expenses
15.04
-6.03%
16.01
-5.94%
17.02
—
Payables
15.04
-6.03%
16.01
-5.94%
17.02
—
Accounts Payable
7.47
-5.65%
7.92
-7.45%
8.56
—
Other Payable
1.02
-9.00%
1.12
-21.87%
1.44
—
Employee Benefits
1.92
-29.56%
2.73
+11.84%
2.44
—
Total Tax Payable
6.55
-5.98%
6.96
-0.84%
7.02
—
Current Debt And Capital Lease Obligation
8.80
+1.07%
8.71
-2.54%
8.94
—
Current Debt
8.52
+0.91%
8.44
-0.15%
8.45
—
Other Current Borrowings
8.52
+0.91%
8.44
-0.15%
8.45
—
Current Capital Lease Obligation
0.29
+5.90%
0.27
-44.12%
0.48
—
Current Deferred Liabilities
2.83
+358.60%
0.62
-89.50%
5.87
—
Current Deferred Revenue
2.83
+358.60%
0.62
-89.50%
5.87
—
Other Current Liabilities
6.50
-12.66%
7.44
-2.65%
7.65
—
Total Non Current Liabilities Net Minority Interest
47.77
-31.01%
69.24
-17.22%
83.65
—
Long Term Debt And Capital Lease Obligation
13.77
-38.21%
22.29
-28.01%
30.96
—
Long Term Debt
13.67
-38.36%
22.18
-27.53%
30.61
—
Long Term Capital Lease Obligation
0.10
-6.73%
0.10
-70.29%
0.35
—
Long Term Provisions
0.33
+21.17%
0.27
-54.56%
0.60
—
Non Current Pension And Other Postretirement Benefit Plans
1.92
-29.56%
2.73
+11.84%
2.44
—
Non Current Deferred Liabilities
0.00
-100.00%
2.83
-38.83%
4.62
—
Non Current Deferred Revenue
0.00
-100.00%
2.83
-38.83%
4.62
—
Non Current Deferred Taxes Liabilities
—
—
9.01
+79.12%
5.03
Other Non Current Liabilities
31.75
-22.81%
41.13
-8.67%
45.03
—
Stockholders Equity
-21.70
-345.69%
8.83
-82.98%
51.90
—
Common Stock Equity
-21.70
-345.69%
8.83
-82.98%
51.90
—
Capital Stock
4.69
+11.81%
4.19
+3.66%
4.04
—
Common Stock
4.69
+11.81%
4.19
+3.66%
4.04
—
Share Issued
93.72
+11.80%
83.83
+3.67%
80.86
—
Ordinary Shares Number
93.70
+11.80%
83.81
+3.67%
80.84
—
Treasury Shares Number
0.02
+0.00%
0.02
+0.00%
0.02
+0.00%
0.02
Additional Paid In Capital
408.03
+4.36%
390.98
+1.75%
384.25
—
Retained Earnings
-435.54
-12.73%
-386.36
-14.68%
-336.89
—
Gains Losses Not Affecting Retained Earnings
1.12
+4040.74%
0.03
-94.55%
0.49
—
Other Equity Adjustments
1.12
+4040.74%
0.03
-94.55%
0.49
—
Total Equity Gross Minority Interest
-21.70
-345.69%
8.83
-82.98%
51.90
—
Total Capitalization
-8.03
-125.89%
31.02
-62.41%
82.51
—
Working Capital
10.06
-80.93%
52.76
-51.32%
108.38
—
Invested Capital
0.48
-98.77%
39.45
-56.62%
90.96
—
Total Debt
22.57
-27.17%
31.00
-22.30%
39.89
—
Capital Lease Obligations
0.38
+2.40%
0.38
-55.09%
0.83
—
Net Tangible Assets
-21.70
-345.69%
8.83
-82.84%
51.48
—
Tangible Book Value
-21.70
-345.69%
8.83
-82.84%
51.48
—
Current Provisions
3.48
+1580.68%
0.21
+21.05%
0.17
—
Financial Assets Designatedas Fair Value Through Profitor Loss Total
10.46
+1.69%
10.28
+4.95%
9.80
—
Investmentin Financial Assets
10.46
+1.69%
10.28
+4.95%
9.80
—
Other Equity Interest
—
—
—
-0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-32.56
-372.14%
-6.90
+86.93%
-52.76
-175.41%
-19.16
Cash Flow From Continuing Operating Activities
-32.56
-372.14%
-6.90
+86.93%
-52.76
-175.41%
-19.16
Net Income From Continuing Operations
-7.57
+84.70%
-49.47
-0.60%
-49.18
+15.36%
-58.10
Depreciation Amortization Depletion
5.09
+155.32%
1.99
+44.08%
1.38
-96.95%
45.41
Depreciation And Amortization
5.09
+155.32%
1.99
+44.08%
1.38
-96.95%
45.41
Other Non Cash Items
0.01
+101.69%
-0.36
-0.56%
-0.35
-366.17%
0.13
Pension And Employee Benefit Expense
0.28
-12.04%
0.32
+140.15%
-0.81
-321.10%
0.36
Stock Based Compensation
4.26
+7.91%
3.94
+53.64%
2.57
-39.59%
4.25
Provisionand Write Offof Assets
-0.97
-229.69%
-0.29
-108.80%
3.33
+296.90%
0.84
Operating Gains Losses
0.31
+156.93%
-0.54
-193.60%
0.58
+205.67%
-0.55
Gain Loss On Investment Securities
—
—
—
-0.91
Unrealized Gain Loss On Investment Securities
-1.59
-19.25%
-1.33
-196.01%
-0.45
-132.87%
1.37
Net Foreign Currency Exchange Gain Loss
0.54
+161.47%
-0.89
-164.98%
1.36
+249.34%
-0.91
Gain Loss On Sale Of PPE
0.47
+2250.00%
0.02
-13.04%
0.02
0.00
Change In Working Capital
-32.09
-181.95%
39.16
+468.34%
-10.63
+14.96%
-12.50
Change In Receivables
—
—
—
-4.20
Changes In Account Receivables
—
—
—
-4.20
Change In Payables And Accrued Expense
—
—
—
-7.66
Change In Payable
—
—
—
-7.66
Change In Account Payable
—
—
—
-7.66
Change In Other Working Capital
—
—
—
-23.43
Change In Other Current Liabilities
—
—
—
22.80
Investing Cash Flow
20.63
+124.24%
9.20
+26.22%
7.29
+288.33%
1.88
Cash Flow From Continuing Investing Activities
20.63
+124.26%
9.20
+26.22%
7.29
+288.28%
1.88
Net PPE Purchase And Sale
-0.20
+48.59%
-0.39
-179.29%
-0.14
+73.83%
-0.54
Purchase Of PPE
-0.35
+10.23%
-0.39
-179.29%
-0.14
+73.83%
-0.54
Sale Of PPE
0.15
0.00
0.00
0.00
Capital Expenditure
-2.35
-501.28%
-0.39
-179.29%
-0.14
+87.52%
-1.12
Net Investment Purchase And Sale
22.77
+137.41%
9.59
+36.32%
7.04
+134.50%
3.00
Purchase Of Investment
—
—
0.00
0.00
Sale Of Investment
22.77
+137.41%
9.59
+36.32%
7.04
+134.50%
3.00
Net Intangibles Purchase And Sale
-2.00
0.00
0.00
+100.00%
-0.59
Purchase Of Intangibles
-2.00
0.00
0.00
+100.00%
-0.59
Net Other Investing Changes
0.06
+6200.00%
0.00
-83.33%
0.01
+700.00%
-0.00
Financing Cash Flow
-1.97
+67.28%
-6.01
-198.98%
6.07
+432.06%
-1.83
Cash Flow From Continuing Financing Activities
-1.97
+67.28%
-6.01
-198.98%
6.07
+432.06%
-1.83
Net Issuance Payments Of Debt
-2.36
+73.58%
-8.94
-0.28%
-8.91
-339.83%
-2.03
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
-2.36
+73.58%
-8.94
-0.28%
-8.91
-339.83%
-2.03
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
-2.36
+73.58%
-8.94
-0.28%
-8.91
-339.83%
-2.03
Net Long Term Debt Issuance
-2.36
+73.58%
-8.94
-0.28%
-8.91
-339.83%
-2.03
Net Common Stock Issuance
—
—
—
—
Cash Dividends Paid
—
—
0.00
0.00
Proceeds From Stock Option Exercised
0.40
-86.51%
2.93
-80.46%
14.98
+7466.16%
0.20
Net Other Financing Charges
—
—
—
—
Changes In Cash
-13.89
-275.11%
-3.70
+90.60%
-39.40
-106.23%
-19.10
Effect Of Exchange Rate Changes
0.27
+154.26%
-0.51
-146.25%
1.09
+355.14%
-0.43
Beginning Cash Position
84.22
+19.29%
70.61
+6.34%
66.40
-36.01%
103.76
End Cash Position
70.61
+6.34%
66.40
+136.35%
28.09
-66.65%
84.22
Free Cash Flow
-34.91
-379.07%
-7.29
+86.22%
-52.90
-160.86%
-20.28
Common Stock Issuance
—
—
—
—
Interest Paid CFF
—
—
0.00
0.00
Interest Received CFI
0.00
0.00
-100.00%
0.39
0.00
Issuance Of Capital Stock
—
—
—
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category